Talc mesothelioma case in South Carolina ends in mistrial for Johnson & Johnson

courthouse
Johnson & Johnson faces more than 9,000 talc lawsuits, according to a recent quarterly filing. (Pixabay)

Right on the heels of a legal defeat for Johnson & Johnson in California, a jury in South Carolina has failed to reach a decision in a case alleging the company's talc baby powder can cause mesothelioma.

Jurors in South Carolina couldn't reach a unanimous decision in the case of Bertila Boyd-Bostic, who passed away last year at age 30 from the cancer, according to Reuters. 

Johnson & Johnson representatives said the company is disappointed the jury didn't reach a decision in its favor, while attorneys for the plaintiffs said they intend retry the case as soon as possible, the news service reports.

RELATED: Johnson & Johnson suffers another cancer-suit loss as talc case count climbs above 9,000 

The mistrial in South Carolina came the same week a jury in Los Angeles ordered J&J to pay $25.75 million in the mesothelioma case of Joanne Anderson. Before that, a jury in New Jersey awarded a $117 million verdict in a case brought by Stephen Lanzo. J&J prevailed in an earlier Los Angeles case alleging a link.

The drugmaker has been battling claims its storied talcum powder can cause ovarian cancer for years, and plaintiffs have increasingly filed lawsuits alleging a link to mesothelioma. 

Johnson & Johnson has denied its talc contains asbestos based on "multiple independent, non-litigation-driven scientific evaluations." But in various cases, plaintiffs' attorneys have presented old documents showing asbestos appeared in some tests and that J&J employees debated internally about the issue.    

RELATED: Asbestos case against Johnson & Johnson, Imerys climbs to $117M in damages  

In all, J&J faces about 9,100 talc lawsuits as of its last quarterly filing with the Securities and Exchange Commission. In previous ovarian cancer cases, the company has won in New Jersey and St. Louis, and has managed to get verdicts of $417 million and $72 million thrown out on appeal. The company is in the process of appealing ovarian cancer losses of $55 million, $70 million and $110 million.

Suggested Articles

Bayer has withdrawn part of a proposed Roundup settlement after a judge questioned how it's handling potential future claims.

Consensus pegs cabotegravir peak sales at £750 million ($945 million), indicating it can grab about one-third of the current PrEP market.

The CEOs for COVID-19 vaccine partners Pfizer and BioNTech are sounding confident in their program as they gear up for phase 3.